Revenue and Volume Growth
Group revenue of $3.95 billion, up 2.3% on a constant currency basis; group volumes up 3.7% and price up 0.5%.
Adjusted EPS Beat and Guidance Outperformance
Adjusted EPS of $1.3493, down 2.4% constant currency year-on-year but ahead of the prior guidance range of $1.30–$1.33.
Strong Cash Generation and Balance Sheet Metrics
Operating cash flow of just over $454 million with operating cash conversion of 91% (target 80%); free cash flow of $360 million; net debt of $526 million (net debt/EBITDA 1.08x) and interest cover 13.7x; $1.4 billion committed facilities.
Shareholder Returns and Capital Allocation
Returned ~EUR 197 million via share buybacks (15 million shares at average EUR 13.10); Board authorized an additional EUR 100 million buyback and commenced an initial EUR 50 million tranche; increased final dividend by 10% to a total EUR 0.4287 per share (payout ratio 35.9%).
Health & Nutrition Outperformance
Health & Nutrition delivered like-for-like revenue growth of 6.8% (volume +7.4%, price -0.6%); total revenue +11.5% including acquisitions; H&N EBITDA $115.8 million, up 16.7% constant currency; EBITDA margin improved to 18.4% (+80 bps).
Performance Nutrition Top-line Momentum and Brand Strength
Performance Nutrition like-for-like revenue +4.5% excluding noncore brands; Optimum Nutrition (ON) like-for-like revenue +6.4% (volume +5%, price +1.4%) with double-digit like-for-like revenue growth in H2 and strong online and international performance.
Dairy Nutrition Solid Volume Growth
Dairy Nutrition like-for-like revenue +5% (volume +4.2%, price +0.8%); continued demand for whey and protein solutions and momentum in new protein solution wins.
Strategic M&A, Capacity Expansion and Transformation
Acquisitions completed (Sweetmix; Scicore completed post year-end), approved capacity expansions (spray drying in U.S., doubling Asian premix capacity), and a group transformation program targeting at least $60 million annual cost savings by 2027 (~40% expected in 2026).
Medium-Term Growth Targets and Guidance
Medium-term targets reiterated: PN organic growth 5–7% p.a., H&N 4–6% p.a.; PN EBITDA margin uplift target of 250 bps by 2028; group EPS growth target 7–11% p.a.; 2026 outlook: PN like-for-like revenue growth 5–7% and H&N revenue growth 4–6%.